Monoclonal antibodyPhase 3 trialInvestigational
Margetuximab
How it works
Binds to the HER2 protein on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Colorectal Cancer— HER2-positive
Efficacy
Studies show that margetuximab can improve response rates and overall survival in patients with HER2-positive metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.